Skip to main content

Table 3 Patient reported outcomes and quality of life

From: Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

  EORTC QLQC30 or PedsQL Hesitancy scale PRO CTCAE Toxicitya
Vaccine dose 1 (− 7) X  X    
D7 (± 1) post dose 1 X    X  
Vaccine dose 2 X     
D7 (± 1) post dose 2 X    X   
3 M post dose 2 X     X 
  1. D day, M month, EORTC QLQ European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, PRO CTCAE Patient Reported Outcomes Common Terminology Criteria for Adverse Events
  2. aMedical record review